IL135232A - 21-hydroxy-6 19-oxidoprogesterone for treating excess of glucocorticoids - Google Patents

21-hydroxy-6 19-oxidoprogesterone for treating excess of glucocorticoids

Info

Publication number
IL135232A
IL135232A IL13523298A IL13523298A IL135232A IL 135232 A IL135232 A IL 135232A IL 13523298 A IL13523298 A IL 13523298A IL 13523298 A IL13523298 A IL 13523298A IL 135232 A IL135232 A IL 135232A
Authority
IL
Israel
Prior art keywords
oxidoprogesterone
glucocorticoids
hydroxy
treating excess
excess
Prior art date
Application number
IL13523298A
Other languages
English (en)
Other versions
IL135232A0 (en
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of IL135232A0 publication Critical patent/IL135232A0/xx
Publication of IL135232A publication Critical patent/IL135232A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13523298A 1997-09-23 1998-09-22 21-hydroxy-6 19-oxidoprogesterone for treating excess of glucocorticoids IL135232A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97116526A EP0903146A1 (fr) 1997-09-23 1997-09-23 21-Hydroy-6,19oxidoprogestérone (21-OH-60P) en tant qu'antiglucocorticoide
PCT/EP1998/006021 WO1999015181A1 (fr) 1997-09-23 1998-09-22 21-hydroxy-6,19-oxydoprogesterone(21oh-6op) et son utilisation en tant que medicament destine a traiter l'exces de glucocorticoides

Publications (2)

Publication Number Publication Date
IL135232A0 IL135232A0 (en) 2001-05-20
IL135232A true IL135232A (en) 2005-05-17

Family

ID=8227390

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13523298A IL135232A (en) 1997-09-23 1998-09-22 21-hydroxy-6 19-oxidoprogesterone for treating excess of glucocorticoids

Country Status (13)

Country Link
US (1) US6303591B1 (fr)
EP (2) EP0903146A1 (fr)
AR (1) AR023008A1 (fr)
AT (1) ATE215373T1 (fr)
AU (1) AU738522B2 (fr)
CA (1) CA2303817C (fr)
DE (1) DE69804659T2 (fr)
DK (1) DK1033990T3 (fr)
ES (1) ES2172937T3 (fr)
IL (1) IL135232A (fr)
PT (1) PT1033990E (fr)
WO (1) WO1999015181A1 (fr)
ZA (1) ZA988674B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1542A (en) 1999-04-30 2006-01-31 Pfizer Prod Inc Glucocorticoid receptor modulators.
US7713989B2 (en) 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
DE60129725T2 (de) * 2000-09-18 2007-12-06 Applied Research Systems Ars Holding N.V. Schwefel analoge von 21-hydroxy-6,19-oxidoprogesteronen (21oh-6op) zur behandlung von glucocorticoidüberschuss
PT1325022E (pt) * 2000-09-18 2006-12-29 Applied Research Systems Método para a preparação de 21-hidroxi-6, 19-oxido-progesterona (210h-60p)
DE60113032T2 (de) 2000-10-30 2006-07-06 Pfizer Products Inc., Groton Glukokortikoidrezeptor-Modulatoren
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
EP1886695A1 (fr) * 2006-06-27 2008-02-13 Speedel Experimenta AG Combinaisons pharmacéutiques avec inhibiteurs de l'aldosterone synthase et antagonistes du recepteur de glucocorticoides où inhibiteurs de la synthese de cortisol où antagonistes du facteur de libération de la corticotropine
CA2660570C (fr) 2006-08-24 2016-08-09 University Of Tennessee Research Foundation Acylanilides substitues et procedes d'utilisation de ceux-ci
EP2576582B1 (fr) 2010-05-26 2019-09-18 Corcept Therapeutics, Inc. Traitement de la dystrophie musculaire
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
MX375256B (es) 2012-07-13 2025-03-06 Gtx Inc Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms).
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
CN107530435A (zh) 2015-03-02 2018-01-02 科赛普特治疗学股份有限公司 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤
CN107530339B (zh) 2015-03-30 2021-03-16 科赛普特治疗学股份有限公司 糖皮质激素受体拮抗剂联合糖皮质激素用于治疗肾上腺功能不全
MX383318B (es) 2015-08-13 2025-03-13 Corcept Therapeutics Inc Metodo para diagnosticar de manera diferencial el sindrome de cushing dependiente de la corticotropina.
KR102197526B1 (ko) 2016-01-19 2020-12-31 코어셉트 쎄라퓨틱스 인코포레이티드 이소성 쿠싱 증후군의 감별 진단
MX393313B (es) 2017-06-20 2025-03-24 Corcept Therapeutics Inc Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide.
JP2022515528A (ja) * 2018-12-28 2022-02-18 パンダ コンサルティング エルエルシー 短時間作用型選択的糖質コルチコイド受容体モジュレーター
EP3941460B1 (fr) 2019-03-18 2025-10-15 Nieman, Lynnette K. Mifepristone pour utilisation dans l'amélioration de la sensibilité à l'insuline

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
ATE332696T1 (de) * 1997-10-06 2006-08-15 Univ Leland Stanford Junior Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen

Also Published As

Publication number Publication date
CA2303817C (fr) 2008-04-01
EP0903146A1 (fr) 1999-03-24
PT1033990E (pt) 2002-07-31
EP1033990B1 (fr) 2002-04-03
AU1334199A (en) 1999-04-12
DK1033990T3 (da) 2002-07-08
WO1999015181A1 (fr) 1999-04-01
AU738522B2 (en) 2001-09-20
ZA988674B (en) 1999-06-28
ATE215373T1 (de) 2002-04-15
ES2172937T3 (es) 2002-10-01
AR023008A1 (es) 2002-09-04
IL135232A0 (en) 2001-05-20
DE69804659D1 (de) 2002-05-08
EP1033990A1 (fr) 2000-09-13
CA2303817A1 (fr) 1999-04-01
DE69804659T2 (de) 2002-10-02
US6303591B1 (en) 2001-10-16

Similar Documents

Publication Publication Date Title
IL135232A (en) 21-hydroxy-6 19-oxidoprogesterone for treating excess of glucocorticoids
EP0874828A4 (fr) Compositions de traitement de la douleur
IL131484A0 (en) Treatment of cardiomyopathy
AP9600840A0 (en) Treatment of ovarian estrogen dependent conditions
AU7582398A (en) Composition for treating skin conditions
PL338082A1 (en) Methods of treating obesity
GB9715295D0 (en) Novel method of treatment
GB9712866D0 (en) Novel method of treatment
GB9707693D0 (en) Novel method of treatment
GB9725114D0 (en) Treatment of pruritus
GB9715298D0 (en) Novel method of treatment
GB9715306D0 (en) Novel method of treatment
IL124419A0 (en) Composition for treating pain
PL341667A1 (en) Method of treating cooped
PL334803A1 (en) Derivatives of imino-aza-antracyclinone for treating amyloidosis
EP1007041A4 (fr) Composition analgesique
PL340430A1 (en) Combination for treating aids
AU7247898A (en) Composition for treating pain
PL335904A1 (en) Application of 7alpha-methyl-17alpha-ethynylestrane derivative for treating arteriosclerosis
EP0912178A4 (fr) Methodes de traitement de l'hypertension
IL120254A0 (en) Composition for treatment of acne
PL327430A1 (en) Set of shaped components
PL313849A1 (en) Beta-aminoesters of o-hydrobenzylamides
TW359161U (en) Apparatus for safeguarding women against incontinenece of urine
GB9705301D0 (en) Method of switching

Legal Events

Date Code Title Description
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
MM9K Patent not in force due to non-payment of renewal fees